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ABSTRACT
Because the microbiology and patient population
of infective endocarditis (IE) have evolved, the
traditional deﬁnition of nosocomial IE may
require revision. The question of whether this
deﬁnition should be extended to 6 months after
discharge was explored, and a high rate of
episodes with nosocomial pathogens (coagulase-
negative staphylococci) and a low rate of episodes
with community pathogens (streptococci) in the
extended nosocomial group were found. There-
fore, modiﬁcation of the traditional deﬁnition is
proposed, distinguishing between early (as tradi-
tionally described) and late nosocomial IE (IE in
association with a signiﬁcant invasive procedure
performed during a hospitalization between
8 weeks and 6 months before the onset of
symptoms).
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Rates of nosocomial infective endocarditis (IE) in
previous studies varied from 7% to 33% [1–4].
Recent series described cases of IE due to patho-
gens that were considered to be nosocomial, e.g.
coagulase-negative staphylococci (CoNS), beyond
the traditional 8-week period [3,5]. This study
involved the current deﬁnition of nosocomial IE
and whether it should be extended to 6 months
after discharge.
Patients older than 16 years with a deﬁnite
diagnosis of IE according to the modiﬁed Duke’s
criteria [6] between June 2000 and December 2006
were included. Nosocomial IE was deﬁned as
diagnosis of IE >72 h after admission to the
hospital (tertiary-care and non-tertiary-care cen-
tre) or acquisition of IE in association with a
signiﬁcant invasive procedure performed during
a recent hospitalization <8 weeks before the onset
of symptoms [1,5]. Cases of healthcare-acquired
IE, e.g. patients undergoing hemodialysis, were
included in the nosocomial group, but patients
who were residents of a nursing home were not.
Extended nosocomial IE was deﬁned as IE
acquired in association with a signiﬁcant invasive
procedure performed during one or more recent
hospitalizations (tertiary-care and non-tertiary-
care centre) between 8 weeks and 6 months
before the onset of symptoms. The 6-month limit
to this deﬁnition was based on the observations of
Ben Ami et al. [3]. Signiﬁcant invasive procedures
included urogenital procedures, gastrointestinal
procedures, surgical intervention and central
venous and arterial catheter placements [3,7].
Patients were treated according to the American
Heart Association guidelines [8,9] and predeﬁned
indications for surgery [10].
Comparisons among patient groups were per-
formed using chi-squared analysis or Fisher’s
exact test for categorical variables. The signiﬁ-
cance level used in univariate analysis was
p <0.05. All p-values were two-sided. Multiple
comparisons were adjusted for using the Bonfer-
roni correction. Statistical analysis was performed
with the SPSS software package (version 15.0;
Chicago, IL, USA).
Two hundred and seventy-two patients experi-
enced 287 episodes of IE. Seventy-seven episodes
(27%) were nosocomial IE according to the
traditional deﬁnition, 35 episodes (12%) belonged
to the extended nosocomial group, and the
remaining 175 episodes (61%) were community-
acquired IE. Staphylococci were the predominant
microorganisms in 112 episodes (39%); 77 of these
episodes involved Staphylococcus aureus and,
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among these, 18 involved methicillin-resistant
S. aureus. Thirty-ﬁve episodes of IE (12%) were
due to CoNS; 23 of these involved methicillin-
resistant isolates. Streptococcal IE was observed
in 83 episodes (29%), 49 of which involved
viridans streptococci. Fifty-two episodes (18%)
were caused by enterococci and 40 episodes
(14%) by other microorganisms (including 28
cases of culture-negative IE and 12 cases due to
rare or fastidious microorganisms). Enterococci
were distributed nearly equally between the three
groups. Table 1 summarizes the distribution of
microorganisms and the type of invasive proce-
dure according to the origin of IE. In the nosoco-
mial and extended nosocomial group, the most
frequent microorganisms involved were staphy-
lococci, whereas in the community-acquired
group, streptococci predominated. In the
extended nosocomial group, six methicillin-
susceptible S. aureus (MSSA) episodes were
registered. The preceding procedures included
placement of an orthopaedic prosthesis in two
episodes, which were complicated by an MSSA
sepsis in one episode and a wound infection due
to MSSA in the other episode; the prosthesis and
the wound were both considered to be the portal
of entry. Neurosurgery was performed in one
episode. Placement of a portacath was registered
in one episode, followed by chemotherapy, and
the catheter was considered to be the focus of
bacteraemia. Replacement of a pacemaker oc-
curred in one episode, but the portal of entry was
probably an abscess on the thumb. One episode
had no clear portal of entry, but metastatic
infection (septic arthritis and osteomyelitis) oc-
curred.
Table 1. Epidemiological and micro-
biological characteristics and the
type of invasive procedure (noso-
comial, extended nosocomial or
community-acquired infective endo-
carditis)
Patient group
Nosocomial
n = 77 (%)
Extended
nosocomial
n = 35 (%)
Community-
acquired
n = 175 (%)
Microbiology
Staphylococcus aureus 28 (37) 7 (20) 42 (24a)
MSSA 17 (22) 6 (17) 36 (21)
MRSA 12 (16) 1 (3) 5 (3a)
CoNS 16 (21) 7 (20b) 12 (7a)
Streptococci 8 (11) 6 (17b) 69 (39a)
Enterococci 15 (20) 8 (23) 29 (17)
Other 9 (12) 7 (20) 24 (14)
Patient characteristics
Age (years) 70 69 66a
Gender (male) 42 (55) 23 (66) 107 (61)
Native valve 37 (49c) 28 (80) 115 (65a)
Prosthetic valve 36 (47c) 5 (14b) 55 (31a)
Other than native
valve and prosthetic valved
3 (4) 2 (6) 6 (3)
Type of proceduree
Urogenital Enterococci (3) Enterococci (5), viridans
streptococci (1)
CNEf (1)
Gastrointestinal Enterococci (3),
MSSA (2), CoNS (2),
S. bovis (1), CNEf (1),
Candida spp. (1)
S. bovis (2), Escherichia coli (1),
CNEf (1)
S. bovis (2)
Catheter CoNS (11), MRSA (10),
MSSA (9), CNEf (7),
enterococci (6),
streptococci (3),
Aspergillus spp. (1),
Candida spp. (1)
CoNS (3), MSSA (2), viridans
streptococci (3), enterococci (1),
CNEf (1)
S. bovis (1)
Cardiac surgery MRSA (8), MSSA (4),
CoNS (4), CNEf (3),
enterococci (3),
Candida spp. (1)
CoNS (1)
Orthopaedic surgery MSSA (1), MRSA (1) MSSA (2)
Thoracic surgery MSSA (1), MRSA (1)
Vascular surgery Enterococci (1) MRSA (1), CoNS (1)
Neurosurgery MSSA (1)
Soft tissue excision MRSA (1), enterococci (1) E. coli (1)
MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; CoNS, coagulase-negative staphy-
lococci; CNE, culture-negative endocarditis.
aCommunity-acquired vs. nosocomial; p <0.05.
bExtended nosocomial vs. community-acquired; p <0.05.
cNosocomial vs. extended nosocomial; p <0.05.
dOther episodes included six pacemakers, two infected pseudo-aneurysms, superinfection of two Bentall aorta
prostheses, and one case of ventricular wall involvement.
eSome episodes of IE were preceded by >1 invasive procedure.
fCulture-negative IE.
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Rates of infection with CoNS were similar
between the nosocomial group and the extended
nosocomial group (p 0.9) but were signiﬁcantly
higher in the extended nosocomial group than in
the community-acquired group (p 0.01). Of the
extended nosocomial CoNS episodes, 43% (3 ⁄ 7)
involved native valves and 57% (4 ⁄ 7) prosthetic
valves (p 1.0; Table 2). Rates of streptococcal
infection were signiﬁcantly higher in the
community-acquired group than in the extended
nosocomial group (p 0.01). In the extended
nosocomial group, four episodes with viridans
streptococci were observed and two with Strepto-
coccus bovis. The preceding procedures in four
episodes with viridans streptococci were a percu-
taneous coronary intervention in one episode,
an implantable cardioverter deﬁbrillator (ICD)
implantation in one episode, a cardiac catheteri-
zation and an intravenous angiography in one
episode, and an episiotomy in one episode. There
were no previous speciﬁc dental procedures in
these episodes. The preceding procedures in two
episodes with Streptococcus bovis included a
sigmoid resection due to a tubular adenoma in
one episode and a gastroscopy and colonoscopy
in the other episode.
This study aimed to reassess the deﬁnition of
nosocomial IE and explore the probable nosoco-
mial origin of IE in cases arising up to 6 months
after discharge. The data document a high rate of
hospital pathogens, e.g. CoNS, and a low rate of
community pathogens, e.g. viridans streptococci,
causing IE up to 6 months after an invasive
procedure during hospitalization. Patients may
become colonized during hospitalization by
microorganisms (e.g. CoNS) associated with long
incubation periods, resulting in the development
of IE >8 weeks after hospitalization. Therefore, a
reclassiﬁcation of the deﬁnition of nosocomial IE
is proposed, distinguishing between early IE
(occurring more than 72 h after admission to the
hospital or within 8 weeks after a signiﬁcant
invasive procedure performed during hospital-
ization) and late nosocomial IE (occurring
between 8 weeks and 6 months after a signiﬁcant
invasive procedure performed during hospital-
ization). A clinically relevant consequence of the
extension of the deﬁnition is that, for patients
with suspected late nosocomial IE, initial therapy
should include antimicrobial agents active against
CoNS, irrespective of prosthetic or native valve
IE. However, more epidemiological studies are
required before drawing ﬁnal conclusions about
the extension of this deﬁnition of nosocomial IE to
6 months after discharge and, until then, the
proposed deﬁnition should be used with caution.
Similar rates of enterococcal IE were observed
in the three groups. These data suggest that
nosocomial enterococcaemia may become a major
criterion for IE as proposed previously for
S. aureus. Currently, nosocomial enterococcaemia
is only a minor criterion in the modiﬁed Duke
criteria, in contrast to community-acquired
enterococcaemia which is a major criterion [6].
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ABSTRACT
Thirty-ﬁve Bacteroides fragilis clinical isolates with
varying susceptibility to meropenem were analy-
sed with a prototype of a double-ended Etest strip
containing meropenem ± EDTA, designed for the
detection of the CﬁA metallo-b-lactamase. Pheno-
typic results obtained with this new Etest strip
were related to the genotype and compared to the
results of the Etest containing imipenem ± EDTA.
Whereas the Etest with imipenem ± EDTA only
allowed detection of isolates with high-level
resistance (both MICs of imipenem and merope-
nem >32 mg ⁄L), reﬂecting the possible underes-
timation of CﬁA prevalence in B. fragilis, the Etest
with meropenem ± EDTA proved to be more
accurate, particularly for isolates with low-level
carbapenem resistance, suggesting its potential
for broader detection of CﬁA production.
Keywords Bacteroides, Etest, metallo-b-lactamase,
phenotypic detection
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Bacteroides fragilis is an important anaerobic path-
ogen commonly associated with polymicrobial
infections. Carbapenems are normally highly
active against B. fragilis. However, carbapenem-
resistant B. fragilis isolates have been reported
[1–15], mainly because of the production of CﬁA,
a class B metallo-b-lactamase (MBL) present in up
to 7% of those isolates [3,4]. This enzyme is
usually poorly expressed, but the insertion of
a variety of insertion sequence (IS) elements
upstream of cﬁA, subsequent to a single genetic
event selected with carbapenems [11,16], switches
on gene expression and leads to high-level carb-
apenem resistance [4,5,11–16]. Thus, it is impor-
tant to detect all B. fragilis isolates that harbour
the cﬁA gene in order to avoid inappropriate
carbapenem usage, which may result in the
selection and emergence of high-level resistance
in these strains. In that respect, enzymatic studies
of CﬁA [17] have shown that meropenem is a
better substrate than imipenem for this MBL of
B. fragilis.
The aim of this preliminary study was to assess
the potential value of a novel Etest strip contain-
ing meropenem ± EDTA to detect carbapenem
resistance due to CﬁA in B. fragilis.
Thirty-ﬁve B. fragilis clinical isolates were
examined. Seventeen of these, displaying either
reduced susceptibility (MIC: >1 and £4 mg ⁄L) or
resistance (MIC: >8 mg ⁄L) to meropenem, were
obtained from different microbiology laboratories
between 2005 and 2007 as part as of a multicentre
survey [2]. Eighteen clinically relevant B. fragilis
isolates susceptible to meropenem (MIC:
<1 mg ⁄L) were collected during 2005 at the
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